UBS AG - Capital/Financing Update 2012

Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-178960

CALCULATION OF REGISTRATION FEE

| Title of Each Class of Securities Offered | Maximum Aggregate Offering Price | Amount
of Registration Fee (1) |
| --- | --- | --- |
| Trigger Phoenix Autocallable Optimization Securities linked to the common stock of Ford Motor Company due on April 26, 2017 | $1,728,000.00 | $198.03 |
| Trigger Phoenix Autocallable Optimization Securities linked to the common stock of Pfizer Inc. due on April 26, 2017 | $2,403,500.00 | $275.44 |
| Trigger Phoenix Autocallable Optimization Securities linked to the common stock of United Technologies Corporation due on April 26, 2017 | $233,500.00 | $26.76 |

(1) Calculated in accordance with Rule 457(r) of the Securities Act of 1933.

PRICING SUPPLEMENT (To Prospectus dated January 11, 2012 and Product Supplement dated January 13, 2012 and Prospectus Supplement dated March 14, 2012)

UBS AG Trigger Phoenix Autocallable Optimization Securities

UBS AG $1,728,000 linked to the common stock of Ford Motor Company due April 26, 2017

UBS AG $2,403,500 linked to the common stock of Pfizer Inc. due April 26, 2017

UBS AG $233,500 linked to the common stock of United Technologies Corporation due April 26, 2017

Investment Description

UBS AG Trigger Phoenix Autocallable Optimization Securities (the Securities) are unsubordinated, unsecured debt securities issued by UBS AG (UBS or the Issuer) linked to the performance of the common stock of a specific company (the underlying stock). UBS will pay a monthly contingent coupon payment if the closing price of the underlying stock on the applicable observation date is equal to or greater than the coupon barrier. Otherwise, no coupon will be paid for the month. UBS will automatically call the Securities early if the closing price of the underlying stock on any observation date (monthly, beginning after 1 year) is equal to or greater than the initial price. If the Securities are called, UBS will pay you the principal amount of your Securities plus the contingent coupon for that month and no further amounts will be owed to you under the Securities. If the Securities are not called prior to maturity and the final price of the underlying stock is equal to or greater than the trigger price (which is the same price as the coupon barrier), UBS will pay you a cash payment at maturity equal to the principal amount of your Securities plus the contingent coupon for the final month. If the final price of the underlying stock is less than the trigger price, UBS will pay you less than the full principal amount, if anything, resulting in a loss on your initial investment that is proportionate to the negative performance of the underlying stock over the term of the Securities and you may lose up to 100% of your initial investment. Investing in the Securities involves significant risks. You may lose some or all of your principal amount. The contingent repayment of principal only applies if you hold the Securities to maturity. Any payment on the Securities, including any repayment of principal, is subject to the creditworthiness of the Issuer. If UBS were to default on its payment obligations you may not receive any amounts owed to you under the Securities and you could lose your entire investment.

Features

q Contingent Coupon UBS will pay a monthly contingent coupon payment if the closing price of the underlying stock on the applicable observation date is equal to or greater than the coupon barrier. Otherwise, no coupon will be paid for the month.

q Automatically Callable UBS will automatically call the Securities and pay you the principal amount of your Securities plus the contingent coupon otherwise due for that month if the closing price of the underlying stock on any observation date (monthly, beginning after 1 year) is greater than or equal to the initial price. If the Securities are not called, investors will have the potential for downside equity market risk at maturity.

q Contingent Repayment of Principal Amount at Maturity If by maturity the Securities have not been called and the price of the underlying stock does not close below the trigger price on the final valuation date, UBS will repay your principal amount per Security at maturity. If the price of the underlying stock closes below the trigger price on the final valuation date, UBS will repay less than the principal amount, if anything, resulting in a loss on your initial investment that is proportionate to the decline in the price of the underlying stock from the trade date to the final valuation date. The contingent repayment of principal only applies if you hold the Securities until maturity. Any payment on the Securities, including any repayment of principal, is subject to the creditworthiness of UBS.

Key Dates

Trade Date	April 20, 2012
Settlement Date	April 25, 2012
Observation Dates*	Monthly (callable after 1 year) (see page 4)
Final Valuation Date*	April 20, 2017
Maturity Date*	April 26, 2017

Subject to postponement in the event of a market disruption event, as described in the TPAOS product supplement.

NOTICE TO INVESTORS: THE SECURITIES ARE SIGNIFICANTLY RISKIER THAN CONVENTIONAL DEBT INSTRUMENTS. THE ISSUER IS NOT NECESSARILY OBLIGATED TO REPAY THE FULL PRINCIPAL AMOUNT OF THE SECURITIES AT MATURITY, AND THE SECURITIES CAN HAVE DOWNSIDE MARKET RISK SIMILAR TO THE UNDERLYING STOCK. THIS MARKET RISK IS IN ADDITION TO THE CREDIT RISK INHERENT IN PURCHASING A DEBT OBLIGATION OF UBS. YOU SHOULD NOT PURCHASE THE SECURITIES IF YOU DO NOT UNDERSTAND OR ARE NOT COMFORTABLE WITH THE SIGNIFICANT RISKS INVOLVED IN INVESTING IN THE SECURITIES.

YOU SHOULD CAREFULLY CONSIDER THE RISKS DESCRIBED UNDER KEY RISKS BEGINNING ON PAGE 6 AND UNDER RISK FACTORS BEGINNING ON PAGE PS-16 OF THE TRIGGER PHOENIX AUTOCALLABLE OPTIMIZATION SECURITIES PRODUCT SUPPLEMENT BEFORE PURCHASING ANY SECURITIES. EVENTS RELATING TO ANY OF THOSE RISKS, OR OTHER RISKS AND UNCERTAINTIES, COULD ADVERSELY EFFECT THE MARKET VALUE OF, AND THE RETURN ON, YOUR SECURITIES. YOU MAY LOSE SOME OR ALL OF YOUR INITIAL INVESTMENT IN THE SECURITIES.

Security Offerings

These terms relate to three separate Securities we are offering. Each of the three Securities is linked to the common stock of a different company and each of the three Securities has a different contingent coupon rate, initial price, trigger price and coupon barrier. Each of the Securities are offered at a minimum investment of 100 Securities at $10.00 per Security (representing a $1,000 investment), and integral multiples of $10.00 in excess thereof. The performance of each Security will not depend on the performance of any other Security.

Underlying Stocks	Stock Ticker	Contingent Coupon Rate	Initial Price	Trigger Price	Coupon Barrier	CUSIP	ISIN
Common stock of Ford Motor Company	F	8.77% per annum	$11.41	$7.42, which is 65% of the Initial Price	$7.42, which is 65% of the Initial
Price	9026M0630	US9026M06302
Common stock of Pfizer Inc.	PFE	7.07% per annum	$22.56	$15.79, which is 70% of the Initial
Price	$15.79, which is 70% of the Initial
Price	9026M0655	US9026M06559
Common stock of United Technologies Corporation	UTX	7.46% per annum	$81.00	$56.70, which is 70% of the Initial Price	$56.70, which is 70% of the Initial Price	9026M0648	US9026M06484

See Additional Information about UBS and the Securities on page 2. The Securities will have the terms set forth in the Trigger Phoenix Autocallable Optimization Securities (TPAOS) product supplement relating to the Securities, dated January 13, 2012, the accompanying prospectus and this pricing supplement.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these Securities or passed upon the adequacy or accuracy of this pricing supplement, or the accompanying product supplement or prospectus. Any representation to the contrary is a criminal offense. The Securities are not deposit liabilities of UBS and are not FDIC insured.

Offering of Securities	Issue Price to Public — Total	Per Security	Underwriting Discount — Total	Per Security	Proceeds to UBS AG — Total	Per Security
Securities linked to the common stock of Ford Motor Company	$1,728,000.00	$10.00	$43,200.00	$0.25	$1,684,800.00	$9.75
Securities linked to the common stock of Pfizer Inc.	$2,403,500.00	$10.00	$60,087.50	$0.25	$2,343,412.50	$9.75
Securities linked to the common stock of United Technologies Corporation	$233,500.00	$10.00	$5,837.50	$0.25	$227,662.50	$9.75

UBS Financial Services Inc. Pricing Supplement dated April 20, 2012 UBS Investment Bank

Additional Information about UBS and the Securities

UBS has filed a registration statement (including a prospectus, as supplemented by a product supplement for the Securities) with the Securities and Exchange Commission, or SEC, for the offerings to which this pricing supplement relates. Before you invest, you should read these documents and any other documents relating to the Securities that UBS has filed with the SEC for more complete information about UBS and these offerings. You may obtain these documents for free from the SEC website at www.sec.gov. Our Central Index Key, or CIK, on the SEC website is 0001114446. Alternatively, UBS will arrange to send you these documents if you so request by calling toll-free 877-387-2275.

You may access these documents on the SEC website at www.sec.gov as follows:

¨ TPAOS Product Supplement dated January 13, 2012:

http://www.sec.gov/Archives/edgar/data/1114446/000119312512011468/d281730d424b2.htm

¨ Prospectus dated January 11, 2012:

http://www.sec.gov/Archives/edgar/data/1114446/000119312512008669/d279364d424b3.htm

References to UBS, we, our and us refer only to UBS AG and not to its consolidated subsidiaries. In this document, Trigger Phoenix Autocallable Optimization Securities or the Securities refer to three different Securities that are offered hereby. Also, references to the TPAOS product supplement mean the UBS product supplement, dated January 13, 2012, and references to accompanying prospectus mean the UBS prospectus, titled Debt Securities and Warrants, dated January 11, 2012.

This pricing supplement, together with the documents listed above, contains the terms of the Securities and supersedes all other prior or contemporaneous oral statements as well as any other written materials including pricing terms, correspondence, trade ideas, structures for implementation, sample structures, brochures or other educational materials of ours. You should carefully consider, among other things, the matters set forth in Key Risks beginning on page 6 and in Risk Factors in the accompanying product supplement, as the Securities involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers before deciding to invest in the Securities.

Investor Suitability

The Securities may be suitable for you if:

¨ You fully understand the risks inherent in an investment in the Securities, including the risk of loss of your entire initial investment.

¨ You can tolerate a loss of all or a substantial portion of your investment and are willing to make an investment that may have the same downside market risk as an investment in the underlying stock.

¨ You believe the closing price of the underlying stock will be equal to or greater than the coupon barrier on the specified observation dates (including the final valuation date).

¨ You understand and accept that you will not participate in any appreciation in the price of the underlying stock and that your potential return is limited to the contingent coupon payments specified in this pricing supplement.

¨ You can tolerate fluctuations in the price of the Securities prior to maturity that may be similar to or exceed the downside price fluctuations of the underlying stock.

¨ You are willing to invest in the Securities based on the contingent coupon rate for such offering of the Securities indicated on the first page of this pricing supplement.

¨ You are willing to forgo dividends paid on the underlying stock.

¨ You are willing to invest in securities that may be called early and you are otherwise willing to hold such securities to maturity, a term of approximately 5 years, and accept that there may be little or no secondary market for the Securities.

¨ You are willing to assume the credit risk of UBS for all payments under the Securities, and understand that if UBS defaults on its obligations you may not receive any amounts due to you including any repayment of principal.

The Securities may not be suitable for you if:

¨ You do not fully understand the risks inherent in an investment in the Securities, including the risk of loss of your entire initial investment.

¨ You require an investment designed to provide a full return of principal at maturity.

¨ You cannot tolerate a loss of all or a substantial portion of your investment, and you are not willing to make an investment that may have the same downside market risk as an investment in the underlying stock.

¨ You believe that the price of the underlying stock will decline during the term of the Securities and is likely to close below the coupon barrier on the specified observation dates and below the trigger price on the final valuation date.

¨ You seek an investment that participates in the full appreciation in the price of the underlying stock or that has unlimited return potential.

¨ You cannot tolerate fluctuations in the price of the Securities prior to maturity that may be similar to or exceed the downside price fluctuations of the underlying stock.

¨ You are unwilling to invest in the Securities based on the contingent coupon rate for such offering of the Securities indicated on the first page of this pricing supplement.

¨ You prefer to receive the dividends paid on the underlying stock.

¨ You are unable or unwilling to hold securities that may be called early, or you are otherwise unable or unwilling to hold such securities to maturity, a term of approximately 5 years, or you seek an investment for which there will be an active secondary market for the Securities.

¨ You are not willing to assume the credit risk of UBS for all payments under the Securities, including any repayment of principal.

The suitability considerations identified above are not exhaustive. Whether or not the Securities are a suitable investment for you will depend on your individual circumstances and you should reach an investment decision only after you and your investment, legal, tax, accounting and other advisors have carefully considered the suitability of an investment in the Securities in light of your particular circumstances. You should also review carefully the Key Risks beginning on page 6 of this pricing supplement for risks related to an investment in the Securities.

Final Terms for Each Offering of the Securities

Issuer	UBS AG, London Branch
Principal Amount	$10.00 per Security
Term (1)	Approximately 5 years, unless called earlier.
Underlying Stock	The common stock of a specific company, as indicated on the first page of this pricing supplement.
Contingent Coupon	If the closing price of the underlying stock is equal to or greater than the coupon barrier on any
observation date, UBS will pay you the contingent coupon applicable to such observation date (as set forth on page 5). If the closing price of the underlying stock is less than the coupon barrier on any observation date, the contingent coupon applicable to such observation date will not be payable and UBS will not make any
payment to you on the relevant coupon payment date (as set forth on page 5). The
contingent coupon will be a fixed amount based upon equal monthly installments at the contingent coupon rate, which is a per annum rate. The table below sets forth the corresponding contingent coupon amount for each Security that would be applicable
to each observation date on which the closing price of the underlying stock is greater than or equal to the coupon barrier. The table below represents a contingent coupon rate of (i) 8.77% per annum for Securities linked to the common stock of Ford
Motor Company, (ii) 7.07% per annum for Securities linked to the common stock of Pfizer Inc. and (iii) 7.46% per annum for Securities linked to the common stock of United Technologies Corporation. Contingent Coupon (per Security)

Ford Motor Company	Pfizer Inc.	United Technologies Corporation
$0.07308	$0.05892	$0.06217

| | Contingent coupon payments on the Securities are not guaranteed. UBS will not pay you the contingent coupon for any observation date on which the
closing price of the underlying stock is less than the coupon barrier. |
| --- | --- |
| Contingent Coupon Rate | The contingent coupon rate is (i) 8.77% per annum for Securities linked to the common stock of Ford Motor
Company, (ii) 7.07% per annum for Securities linked to the common stock of Pfizer Inc. and (iii) 7.46% per annum for Securities linked to the common stock of United Technologies
Corporation. |

| Automatic Call Feature | The Securities will be called automatically if the closing price of the underlying stock on any
observation date (monthly, beginning April 22, 2013) is equal to or greater than the initial price. If the Securities are called on any observation date (monthly, beginning April 22, 2013), UBS will pay you on the corresponding coupon payment date (which will be the call settlement date) a cash
payment per Security equal to your principal amount plus the contingent coupon otherwise due on such date pursuant to the contingent coupon feature. No further amounts will be owed to you under the Securities. |
| --- | --- |
| Payment at Maturity (per Security) | I f the Securities are not called and the final price is equal to or greater than the trigger
price and coupon barrier, UBS will pay you a cash payment per Security on the maturity date equal to $10.00 plus the contingent coupon otherwise due on the maturity date. If the Securities are not called and the final price is less than the trigger price, UBS
will pay you a cash payment on the maturity date of less than the principal amount, if anything, resulting in a loss on your initial investment that is proportionate to the negative underlying return, for an amount equal to: $10.00 + ($10.00 × Underlying Return) |
| Underlying Return | Final Price Initial Price Initial Price |
| Trigger Price | A percentage of the initial price of the underlying stock, as specified on the first page of this pricing supplement (as may be adjusted in the case of
certain adjustment events as described under General Terms of the Securities Antidilution Adjustments in the TPAOS product supplement). |
| Coupon Barrier | A percentage of the initial price of the underlying stock, as specified on the first page of this pricing supplement (as may be adjusted in the case of
certain adjustment events as described under General Terms of the Securities Antidilution Adjustments in the TPAOS product supplement). |
| Initial Price | The closing price of the underlying stock on the trade date, as specified on the first page of this pricing supplement (as may be adjusted in the case
of certain adjustment events as described under General Terms of the Securities Antidilution Adjustments in the TPAOS product supplement). |
| Final Price | The closing price of the underlying stock on the final valuation date, as determined by the calculation agent. |
| Coupon Payment Dates | Two business days following each observation date, except that the coupon payment date for the final valuation date is the maturity
date. |

(1) Subject to the market disruption event provisions set forth in the TPAOS product supplement beginning on page PS-34.

Investment Timeline

INVESTING IN THE SECURITIES INVOLVES SIGNIFICANT RISKS. YOU MAY LOSE SOME OR ALL OF YOUR PRINCIPAL AMOUNT. ANY PAYMENT ON THE SECURITIES, INCLUDING ANY REPAYMENT OF PRINCIPAL, IS SUBJECT TO THE CREDITWORTHINESS OF UBS. IF UBS WERE TO DEFAULT ON ITS PAYMENT OBLIGATIONS, YOU MAY NOT RECEIVE ANY AMOUNTS OWED TO YOU UNDER THE SECURITIES AND YOU COULD LOSE YOUR ENTIRE INVESTMENT.

Observation Dates (1) and Coupon Payment Dates

Observation Dates	Coupon Payment Dates	Observation Dates	Coupon Payment Dates	Observation Dates	Coupon Payment Dates
May 21, 2012*	May 23, 2012	January 21, 2014	January 23, 2014	September 21, 2015	September 23, 2015
June 20, 2012*	June 22, 2012	February 20, 2014	February 24, 2014	October 20, 2015	October 22, 2015
July 20, 2012*	July 24, 2012	March 20, 2014	March 24, 2014	November 20, 2015	November 24, 2015
August 20, 2012*	August 22, 2012	April 21, 2014	April 23, 2014	December 21, 2015	December 23, 2015
September 20, 2012*	September 24, 2012	May 20, 2014	May 22, 2014	January 20, 2016	January 22, 2016
October 22, 2012*	October 24, 2012	June 20, 2014	June 24, 2014	February 22, 2016	February 24, 2016
November 20, 2012*	November 23, 2012	July 21, 2014	July 23, 2014	March 21, 2016	March 23, 2016
December 20, 2012*	December 24, 2012	August 20, 2014	August 22, 2014	April 20, 2016	April 22, 2016
January 22, 2013*	January 24, 2013	September 22, 2014	September 24, 2014	May 20, 2016	May 24, 2016
February 20, 2013*	February 22, 2013	October 20, 2014	October 22, 2014	June 20, 2016	June 22, 2016
March 20, 2013*	March 22, 2013	November 20, 2014	November 24, 2014	July 20, 2016	July 22, 2016
April 22, 2013	April 24, 2013	December 22, 2014	December 24, 2014	August 22, 2016	August 24, 2016
May 20, 2013	May 22, 2013	January 20, 2015	January 22, 2015	September 20, 2016	September 22, 2016
June 20, 2013	June 24, 2013	February 20, 2015	February 24, 2015	October 20, 2016	October 24, 2016
July 22, 2013	July 24, 2013	March 20, 2015	March 24, 2015	November 21, 2016	November 23, 2016
August 20, 2013	August 22, 2013	April 20, 2015	April 22, 2015	December 20, 2016	December 22, 2016
September 20, 2013	September 24, 2013	May 20, 2015	May 22, 2015	January 20, 2017	January 24, 2017
October 21, 2013	October 23, 2013	June 22, 2015	June 24, 2015	February 21, 2017	February 23, 2017
November 20, 2013	November 22, 2013	July 20, 2015	July 22, 2015	March 20, 2017	March 22, 2017
December 20, 2013	December 24, 2013	August 20, 2015	August 24, 2015	April 20, 2017	April 26, 2017

The Securities are not callable until the twelfth observation date, which is April 22, 2013.

(1) Subject to the market disruption event provisions set forth in the TPAOS product supplement beginning on page PS-34.

Key Risks

An investment in any offering of the Securities involves significant risks. Investing in the Securities is not equivalent to investing in the underlying stock. Some of the risks that apply to each offering of the Securities are summarized below, but we urge you to read the more detailed explanation of risks relating to the Securities in the Risk Factors section of the TPAOS product supplement. We also urge you to consult your investment, legal, tax, accounting and other advisors before you invest in the Securities.

¨ Risk of loss at maturity The Securities differ from ordinary debt securities in that UBS will not necessarily repay the full principal amount of the Securities at maturity. If the Securities are not called, UBS will repay you the principal amount of your Securities in cash only if the final price of the underlying stock is greater than or equal to the trigger price and will only make such payment at maturity. If the Securities are not called and the final price is less than the trigger price, you will lose some or all of your initial investment in an amount proportionate to the decline in the price of the underlying stock.

¨ The contingent repayment of principal applies only at maturity You should be willing to hold your Securities to maturity. If you are able to sell your Securities prior to maturity in the secondary market, you may have to sell them at a loss relative to your initial investment even if the price of the underlying stock is above the trigger price.

¨ You may not receive any contingent coupons UBS will not necessarily make periodic coupon payments on the Securities. If the closing price of the underlying stock on an observation date is less than the coupon barrier, UBS will not pay you the contingent coupon applicable to such observation date. If the closing price of the underlying stock is less than the coupon barrier on each of the observation dates, UBS will not pay you any contingent coupons during the term of, and you will not receive a positive return on, your Securities. Generally, this non-payment of the contingent coupon coincides with a period of greater risk of principal loss on your Securities.

¨ Your potential return on the Securities is limited and you will not participate in any appreciation of the underlying stock The return potential of the Securities is limited to the pre-specified contingent coupon rate, regardless of the appreciation of the underlying stock. In addition, the total return on the Securities will vary based on the number of observation dates on which the requirements of the contingent coupon have been met prior to maturity or an automatic call. Further, if the Securities are called due to the automatic call feature, you will not accrue or receive any contingent coupons or any other payment in respect of any observation dates after the applicable call settlement date. Since the Securities could be called as early as the twelfth observation date, the total return on the Securities could be minimal. If the Securities are not called, you will not participate in any appreciation in the price of the underlying stock even though you will be subject to the underlying stocks risk of decline. As a result, the return on an investment in the Securities could be less than the return on a direct investment in the underlying stock.

¨ Higher contingent coupon rates are generally associated with a greater risk of loss Greater expected volatility with respect to the underlying stock reflects a higher expectation as of the trade date that the price of such underlying stock could close below its trigger price on the final valuation date of the Securities. This greater expected risk will generally be reflected in a higher contingent coupon rate for that Security. However, while the contingent coupon rate is set on the trade date, an underlying stocks volatility can change significantly over the term of the Securities. The price of the underlying stock for your Securities could fall sharply, which could result in a significant loss of principal.

¨ Reinvestment risk The Securities will be called automatically if the closing price of the underlying stock is equal to or greater than the initial price on any observation date (monthly, beginning after 1 year). In the event that the Securities are called prior to maturity, there is no guarantee that you will be able to reinvest the proceeds from an investment in the Securities at a comparable rate of return for a similar level of risk. To the extent you are able to reinvest such proceeds in an investment comparable to the Securities, you will incur transaction costs and the original issue price for such an investment is likely to include certain built - in costs such as dealer discounts and hedging costs.

¨ Credit risk of UBS The Securities are unsubordinated, unsecured debt obligations of the issuer, UBS, and are not, either directly or indirectly, an obligation of any third party. Any payment to be made on the Securities, including payments in respect of an automatic call, contingent coupon payment or any contingent repayment of principal provided at maturity, depends on the ability of UBS to satisfy its obligations as they come due. As a result, the actual and perceived creditworthiness of UBS may affect the market value of the Securities and, in the event UBS were to default on its obligations, you may not receive any amounts owed to you under the terms of the Securities and you could lose your entire initial investment.

¨ Single stock risk The price of the underlying stock can rise or fall sharply due to factors specific to that underlying stock and the issuer of such underlying stock (the underlying stock issuer), such as stock price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as well as general market factors, such as general stock market volatility and levels, interest rates and economic and political conditions. You, as an investor in the Securities, should make your own investigation into the respective underlying stock issuer and the underlying stock for your Securities. For additional information regarding each underlying stock issuer, please see Information about the Underlying Stocks and Ford Motor Company, Pfizer Inc. and United Technologies Corporation. in this pricing supplement and the respective underlying stock issuers SEC filings referred to in these sections. We urge you to review financial and other information filed periodically by the applicable underlying stock issuer with the SEC.

¨ No assurance that the investment view implicit in the Securities will be successful It is impossible to predict whether and the extent to which the price of the underlying stock will rise or fall. The closing price of the underlying stock will be influenced by complex and interrelated political, economic, financial and other factors that affect the underlying stock. You should be willing to accept the downside risks of owning equities in general and the underlying stock in particular, and the risk of losing some or all of your initial investment.

¨ Owning the Securities is not the same as owning the underlying stock The return on your Securities is unlikely to reflect the return you would realize if you actually owned the underlying stock. For instance, you will not receive or be entitled to receive any dividend payments or other distributions on the underlying stock during the term of your Securities. As an owner of the Securities, you will not have voting rights or any other rights that holders of the underlying stock may have. Furthermore, the underlying stock may appreciate substantially during the term of the Securities and you will not participate in such appreciation.

¨ There is no affiliation between the respective underlying stock issuers and UBS, and UBS is not responsible for any disclosure by such issuer We are not affiliated with any underlying stock issuer. However, we and our affiliates may currently, or from time to time in the future engage in business with an underlying stock issuer. Nevertheless, neither we nor our affiliates assume any responsibility for the accuracy or the completeness of any information about the underlying stock and the underlying stock issuer. You, as an investor in the Securities, should make your own investigation into the underlying stock and the underlying stock issuer for your Securities. The underlying stock issuer is not involved in the Securities offered hereby in any way and has no obligation of any sort with respect to your Securities. The underlying stock issuer has no obligation to take your interests into consideration for any reason, including when taking any corporate actions that might affect the value of your Securities.

¨ The calculation agent can make adjustments that affect the payment to you at maturity For certain corporate events affecting the underlying stock, the calculation agent may make adjustments to the initial price, the coupon barrier and trigger price applicable to such underlying stock. However, the calculation agent will not make an adjustment in response to all events that could affect the underlying stock. If an event occurs that does not require the calculation agent to make an adjustment, the value of the Securities may be materially and adversely affected. In addition, all determinations and calculations concerning any such adjustments will be made by the calculation agent. You should be aware that the calculation agent may make any such adjustment, determination or calculation in a manner that differs from that discussed in the TPAOS product supplement or this pricing supplement as necessary to achieve an equitable result. Following certain corporate events relating to the respective issuer of the underlying stock where such issuer is not the surviving entity, the amount of cash you receive at maturity may be based on the common stock of a successor to the respective underlying stock issuer in combination with any cash or any other assets distributed to holders of the underlying stock in such corporate event. If the issuer of an underlying stock becomes subject to (i) a corporate event whereby the underlying stock is exchanged solely for cash or (ii) a merger or combination with UBS or any of its affiliates, the amount you receive at maturity may be based on the common stock issued by another company. The occurrence of these corporate events and the consequent adjustments may materially and adversely affect the value of the Securities. For more information, see the section General Terms of the Securities Antidilution Adjustments beginning on page PS-35 of the product supplement. Regardless of any of the events discussed above, any payment on the Securities is subject to the creditworthiness of UBS.

¨ There may be little or no secondary market The Securities will not be listed or displayed on any securities exchange or any electronic communications network. There can be no assurance that a secondary market for the Securities will develop. UBS Securities LLC and other affiliates of UBS may make a market in each offering of the Securities, although they are not required to do so and may stop making a market at any time. If you are able to sell your Securities prior to maturity, you may have to sell them at a substantial loss.

¨ Price of Securities prior to maturity The market price of the Securities will be influenced by many unpredictable and interrelated factors, including the price of the underlying stock; the volatility of the underlying stock; the dividend rate paid on the underlying stock; the time remaining to the maturity of the Securities; interest rates in the markets; geopolitical conditions and economic, financial, political, force majeure and regulatory or judicial events; and the creditworthiness of UBS.

¨ Impact of fees on secondary market prices Generally, the price of the Securities in the secondary market is likely to be lower than the issue price to public since the issue price included, and the secondary market prices are likely to exclude, commissions, hedging costs or other compensation paid with respect to the Securities.

¨ Potential UBS impact on price Trading or transactions by UBS or its affiliates in the underlying stock and/or over-the-counter options, futures or other instruments with returns linked to the performance of the underlying stock, may adversely affect the market price of the underlying stock and, therefore, the market value of the Securities.

¨ Potential conflict of interest UBS and its affiliates may engage in business with the issuer of the underlying stock, which may present a conflict between the obligations of UBS and you, as a holder of the Securities. There are also potential conflicts of interest between you and the calculation agent, which will be an affiliate of UBS. The calculation agent will determine whether the contingent coupon is payable to you on any coupon payment date or whether the Securities are subject to an automatic call, or the amount you receive at maturity of the Securities. The calculation agent may postpone any observation date (including the final valuation date) if a market disruption event occurs and is continuing on such date.

¨ Potentially inconsistent research, opinions or recommendations by UBS UBS and its affiliates publish research from time to time on financial markets and other matters that may influence the value of the Securities, or express opinions or provide recommendations that are inconsistent with purchasing or holding the Securities. Any research, opinions or recommendations expressed by UBS or its affiliates may not be consistent with each other and may be modified from time to time without notice. Investors should make their own independent investigation of the merits of investing in the Securities and the underlying stock to which the Securities are linked.

¨ Dealer incentives UBS and its affiliates act in various capacities with respect to the Securities. We and our affiliates may act as a principal, agent or dealer in connection with the sale of the Securities. Such affiliates, including the sales representatives, will derive compensation from the distribution of the Securities and such compensation may serve as an incentive to sell these Securities instead of other investments. We will pay total underwriting compensation of $0.25 per Security to any of our affiliates acting as agents or dealers in connection with the distribution of the Securities.

¨ Uncertain tax treatment Significant aspects of the tax treatment of the Securities are uncertain. You should consult your own tax advisor about your tax situation.

Hypothetical Examples of How the Securities Might Perform

The examples below illustrate the payment upon a call or at maturity for a $10.00 Security on a hypothetical offering of the Securities, with the following assumptions (the actual terms for each Security are specified on the first page of this pricing supplement; amounts may have been rounded for ease of reference):

Principal Amount:	$10.00
Term:	5 years
Initial Price:	$55.00
Contingent Coupon Rate:	7.50% per annum (or 0.625% per month)
Contingent Coupon:	$0.0625 per month
Observation Dates:	Monthly (callable after 1 year)
Trigger Price:	$35.75 (which is 65% of the Initial Price)
Coupon Barrier:	$35.75 (which is 65% of the Initial Price)

Example 1 Securities are Called on the Twelfth Observation Date

Date	Closing Price	Payment (per Security)
First Observation Date	$60.00 (at or above Initial Price)	$0.0625 (Contingent Coupon Not Callable)
Second Observation Date	$45.00 (at or above Coupon Barrier; below Initial Price)	$0.0625 (Contingent Coupon)
Third to Eleventh Observation Dates	Various (all at or above Coupon Barrier; below Initial Price)	$0.5625 (Contingent Coupon)
Twelfth Observation Date	$60.00 (at or above Initial Price)	$10.0625 (Settlement Amount)
	Total Payment:	$10.750 (7.50% return)

Since the Securities are called on the twelfth observation date (which is approximately one year after the trade date and is the first observation date on which they are callable), UBS will pay you on the call settlement date a total of $10.0625 per Security, reflecting your principal amount plus the applicable contingent coupon. When added to the contingent coupon payments of $0.6875 received in respect of prior observation dates, UBS will have paid you a total of $10.750 per Security for a 7.50% total return on the Securities. No further amount will be owed to you under the Securities.

Example 2 Securities are NOT Called and the Final Price of the Underlying Stock is at or above the Trigger Price

Date	Closing Price	Payment (per Security)
First Observation Date	$50.00 (at or above Coupon Barrier; below Initial Price)	$0.0625 (Contingent Coupon)
Second Observation Date	$35.00 (below Coupon Barrier;)	$0.00
Third Observation Date	$30.00 (below Coupon Barrier;)	$0.00
Fourth to Fifty-Ninth Observation Dates	Various (all below Coupon Barrier)	$0.00
Final Valuation Date	$50.00 (at or above Trigger Price and Coupon Barrier; below Initial Price)	$10.0625 (Settlement Amount)
	Total Payment:	$10.125 (1.25% return)

At maturity, UBS will pay you a total of $10.0625 per Security, reflecting your principal amount plus the applicable contingent coupon. When added to the contingent coupon payment of $0.0625 received in respect of prior observation dates, UBS will have paid you a total of $10.125 per Security for a 1.25% total return on the Securities.

Example 3 Securities are NOT Called and the Final Price of the Underlying Stock is below the Trigger Price

Date	Closing Price	Payment (per Security)
First Observation Date	$50.00 (at or above Coupon Barrier; below Initial Price)	$0.0625 (Contingent Coupon)
Second Observation Date	$45.00 (at or above Coupon Barrier; below Initial Price)	$0.0625 (Contingent Coupon)
Third Observation Date	$40.00 (at or above Coupon Barrier; below Initial Price)	$0.0625 (Contingent Coupon)
Fourth to Fifty-Ninth Observation Dates	Various (all at or above Coupon Barrier; below Initial Price)	$3.50 (Contingent Coupon)
Final Valuation Date	$22.00 (below Trigger Price and Coupon Barrier)	$10.00 + [$10.00 × Underlying Return] =
		$10.00 + [$10.00 × -60%] =
		$10.00 - $6.00 =
		$ 4.00 (Payment at Maturity)
	Total Payment	$ 7.6875 (-23.125% return)

Since the Securities are not called and the final price of the underlying stock is below the trigger price, at maturity UBS will pay you $4.00 per Security. When added to the contingent coupon payments of $3.6875 received in respect of prior observation dates, UBS will have paid you $7.6875 per Security for a loss on the Securities of 23.125%.

The Securities differ from ordinary debt securities in that UBS is not necessarily obligated to repay the full amount of your initial investment. If the Securities are not called on any observation date, you may lose some or all of your initial investment. Specifically, if the Securities are not called and the final price is less than the trigger price, you will lose 1% (or a fraction thereof) of your principal amount for each 1% (or a fraction thereof) that the underlying return is less than zero.

Any payment on the Securities, including payments in respect of an automatic call, contingent coupon or any repayment of principal provided at maturity, is dependent on the ability of UBS to satisfy its obligations when they come due. If UBS is unable to meet its obligations, you may not receive any amounts due to you under the Securities.

Information about the Underlying Stocks

All disclosures contained in this pricing supplement regarding each underlying stock are derived from publicly available information. Neither UBS nor any of its affiliates assumes any responsibilities for the adequacy or accuracy of information about any underlying stock contained in this pricing supplement. You should make your own investigation into each underlying stock.

Included on the following pages is a brief description of each underlying stock issuer. This information has been obtained from publicly available sources. Set forth below is a table that provides the quarterly high and low closing prices for each underlying stock. The information given below is for the four calendar quarters in each of 2008, 2009, 2010, 2011 and the first calendar quarter of 2012. Partial data is provided for the second calendar quarter of 2012. We obtained the closing price information set forth below from the Bloomberg Professional © service (Bloomberg) without independent verification. You should not take the historical prices of each underlying stock as an indication of future performance.

Each of the underlying stocks are registered under the Securities Exchange Act of 1934, as amended (the Exchange Act). Companies with securities registered under the Exchange Act are required to file financial and other information specified by the SEC periodically. Information filed by each issuer of the underlying stocks with the SEC can be reviewed electronically through a website maintained by the SEC. The address of the SECs website is http://www.sec.gov. Information filed with the SEC by each issuer of the underlying stocks under the Exchange Act can be located by reference to its SEC file number provided below. In addition, information filed with the SEC can be inspected and copied at the Public Reference Section of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Copies of this material can also be obtained from the Public Reference Section, at prescribed rates.

Ford Motor Company

According to publicly available information, Ford Motor Company (Ford) is a producer of cars and trucks. Ford and its subsidiaries also engage in other businesses, including financing vehicles. Ford operates in two sectors: Automotive and Financial Services. The Automotive sector includes the operations of Ford North America, Ford South America, Ford Europe and Ford Asia Pacific Africa segments. Fords vehicle brands include Ford and Lincoln. Substantially all of Fords cars, trucks and parts are marketed through retail dealers in North America, and through distributors and dealers (collectively, dealerships) outside of North America, the substantial majority of which are independently owned. The Financial Services sector includes the operations of Ford Motor Credit Company (Ford Credit), which offers a wide variety of automotive financing products to and through automotive dealers. The predominant share of Ford Credits business consists of financing Fords vehicles and supporting its dealers. In addition to the products Ford sells to its dealerships for retail sale, it also sells cars and trucks to its dealerships for sale to fleet customers, including daily rental car companies, commercial fleet customers, leasing companies and governments. Through its dealer network and other channels, Ford provides retail customers with a wide range of after-sale vehicle services and products, including maintenance and light repair, heavy repair, collision, vehicle accessories and extended service warranty. Information filed by Ford with the SEC under the Exchange Act can be located by reference to its SEC file number: 001-03950, or its CIK Code: 0000037996. Fords website is http://www.ford.com. Fords common stock is listed on the New York Stock Exchange under the ticker symbol F.

Information from outside sources is not incorporated by reference in, and should not be considered part of, this pricing supplement or any accompanying prospectus. We make no representation or warranty as to the accuracy or completeness of the information contained in outside sources.

Historical Information

The following table sets forth the quarterly high and low closing prices for Fords common stock, based on the daily closing prices on the primary exchange for Ford. We obtained the closing prices below based from Bloomberg, without independent verification. The closing prices may be adjusted by Bloomberg for corporate actions such as stock splits, public offerings, mergers and acquisitions, spin-offs, extraordinary dividends, delistings and bankruptcy. We make no representation or warranty as to the accuracy or completeness of the information obtained from Bloomberg. The closing price of Ford on April 20, 2012 was $11.41. The historical performance of the underlying stock should not be taken as indication of the future performance of the underlying stock during the term of the Securities.

Quarter Begin — 1/2/2008		3/31/2008		Quarterly High — $ 6.85	Quarterly Low — $ 5.11	Quarterly Close — $ 5.72
4/1/2008		6/30/2008		$ 8.48	$ 4.81	$ 4.81
7/1/2008		9/30/2008		$ 6.03	$ 4.17	$ 5.20
10/1/2008		12/31/2008		$ 4.55	$ 1.26	$ 2.29
1/2/2009		3/31/2009		$ 2.94	$ 1.58	$ 2.63
4/1/2009		6/30/2009		$ 6.41	$ 2.74	$ 6.07
7/1/2009		9/30/2009		$ 8.44	$ 5.35	$ 7.21
10/1/2009		12/31/2009		$ 10.20	$ 6.84	$ 10.00
1/4/2010		3/31/2010		$ 14.10	$ 10.28	$ 12.57
4/1/2010		6/30/2010		$ 14.46	$ 9.88	$ 10.08
7/1/2010		9/30/2010		$ 13.16	$ 10.16	$ 12.24
10/1/2010		12/31/2010		$ 17.00	$ 12.26	$ 16.79
1/3/2011		3/31/2011		$ 18.79	$ 14.01	$ 14.91
4/1/2011		6/30/2011		$ 15.79	$ 12.78	$ 13.79
7/1/2011		9/30/2011		$ 14.12	$ 9.62	$ 9.67
10/3/2011		12/30/2011		$ 12.51	$ 9.37	$ 10.76
1/3/2012		3/30/2012		$ 12.96	$ 11.13	$ 12.49
4/2/2012	*	4/20/2012	*	$ 12.64	$ 11.41	$ 11.41

As of the date of this pricing supplement, available information for the second calendar quarter of 2012 includes data for the period from April 2, 2012 through April 20, 2012. Accordingly, the Quarterly High, Quarterly Low and Quarterly Close data indicated are for this shortened period only and do not reflect complete data for the second calendar quarter of 2012.

The graph below illustrates the performance of Fords common stock from January 3, 2000 through April 20, 2012, based on information from Bloomberg. The dotted line represents the coupon barrier and trigger price of $7.42, which is equal to 65% of the closing price on April 20, 2012. Past performance of the underlying stock is not indicative of the future performance of the underlying stock.

Pfizer Inc.

According to publicly available information, Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. Pfizer applies science and global resources to improve health and well-being at every stage of life. Pfizer manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition. Its diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the worlds best-known consumer healthcare products. Pfizer also collaborates with other biopharmaceutical companies, healthcare providers, governments and local communities to support and expand access to healthcare around the world. Information filed by Pfizer with the SEC under the Exchange Act can be located by reference to its SEC file number: 001-03619, or its CIK Code: 0000078003. Pfizers website is http://www.pfizer.com. Pfizers common stock is listed on the New York Stock Exchange under the ticker symbol PFE.

Historical Information

The following table sets forth the quarterly high and low closing prices for Pfizers common stock, based on the daily closing prices on the primary exchange for Pfizer. We obtained the closing prices below based from Bloomberg, without independent verification. The closing prices may be adjusted by Bloomberg for corporate actions such as stock splits, public offerings, mergers and acquisitions, spin-offs, extraordinary dividends, delistings and bankruptcy. We make no representation or warranty as to the accuracy or completeness of the information obtained from Bloomberg. The closing price of Pfizer on April 20, 2012 was $22.56. The historical performance of the underlying stock should not be taken as indication of the future performance of the underlying stock during the term of the Securities.

Quarter Begin — 1/2/2008		3/31/2008		Quarterly High — $24.08	Quarterly Low — $20.50	Quarterly Close — $20.93
4/1/2008		6/30/2008		$21.51	$17.17	$17.47
7/1/2008		9/30/2008		$19.97	$17.17	$18.44
10/1/2008		12/31/2008		$19.00	$14.45	$17.71
1/2/2009		3/31/2009		$18.27	$11.66	$13.62
4/1/2009		6/30/2009		$15.34	$13.04	$15.00
7/1/2009		9/30/2009		$16.86	$14.20	$16.55
10/1/2009		12/31/2009		$18.85	$16.15	$18.19
1/4/2010		3/31/2010		$20.00	$16.91	$17.15
4/1/2010		6/30/2010		$17.29	$14.26	$14.26
7/1/2010		9/30/2010		$17.41	$14.14	$17.17
10/1/2010		12/31/2010		$17.79	$16.29	$17.51
1/3/2011		3/31/2011		$20.38	$17.68	$20.31
4/1/2011		6/30/2011		$21.45	$19.79	$20.60
7/1/2011		9/30/2011		$20.78	$16.66	$17.68
10/3/2011		12/30/2011		$21.83	$17.33	$21.64
1/3/2012		3/30/2012		$22.66	$20.95	$22.66
4/2/2012	*	4/20/2012	*	$22.61	$21.85	$22.56

As of the date of this pricing supplement, available information for the second calendar quarter of 2012 includes data for the period from April 2, 2012 through April 20, 2012. Accordingly, the Quarterly High, Quarterly Low and Quarterly Close data indicated are for this shortened period only and do not reflect complete data for the second calendar quarter of 2012.

The graph below illustrates the performance of Pfizers common stock from January 3, 2000 through April 20, 2012, based on information from Bloomberg. The dotted line represents the coupon barrier and trigger price of $15.79 which is equal to 70% of the closing price on April 20, 2012. Past performance of the underlying stock is not indicative of the future performance of the underlying stock.

United Technologies Corporation

According to publicly available information, United Technologies Corporation (United Technologies) provides technology products and services to the building systems and aerospace industries. United Technologies operating units include businesses with operations throughout the world. It operates in six segments: Otis, Carrier, United Technologies Fire & Security, Pratt & Whitney, Hamilton Sundstrand and Sikorsky. Otis is a provider of elevators, escalators, moving walkways and services. Carrier is a provider of heating, ventilating, air conditioning and refrigeration systems including controls for residential, commercial, industrial and transportation applications. United Technologies Fire & Security is a provider of fire and special hazard detection and suppression systems, firefighting equipment, security, monitoring and rapid response systems and service, and security personnel services. Pratt & Whitney is a provider of commercial, military, business jet and general aviation aircraft engines, parts and services, industrial gas turbines, geothermal power systems and space propulsion. Hamilton Sundstrand is a provider of aerospace, industrial, and aftermarket services. Sikorsky is a provider of military and commercial helicopters, aftermarket helicopter, and aircraft parts and services. Information filed by United Technologies with the SEC under the Exchange Act can be located by reference to its SEC file number: 001-00812, or its CIK Code: 0000101829. United Technologies website is http://www.utc.com. United Technologies common stock is listed on the New York Stock Exchange under the ticker symbol UTX.

Historical Information

The following table sets forth the quarterly high and low closing prices for United Technologies common stock, based on the daily closing prices on the primary exchange for United Technologies. We obtained the closing prices below based from Bloomberg, without independent verification. The closing prices may be adjusted by Bloomberg for corporate actions such as stock splits, public offerings, mergers and acquisitions, spin-offs, extraordinary dividends, delistings and bankruptcy. We make no representation or warranty as to the accuracy or completeness of the information obtained from Bloomberg. The closing price of United Technologies on April 20, 2012 was $81.00. The historical performance of the underlying stock should not be taken as indication of the future performance of the underlying stock during the term of the Securities.

Quarter Begin — 1/2/2008		3/31/2008		Quarterly High — $76.28	Quarterly Low — $66.23	Quarterly Close — $68.82
4/1/2008		6/30/2008		$75.16	$61.15	$61.70
7/1/2008		9/30/2008		$67.42	$56.66	$60.06
10/1/2008		12/31/2008		$59.12	$43.22	$53.60
1/2/2009		3/31/2009		$54.95	$37.56	$42.98
4/1/2009		6/30/2009		$56.49	$43.88	$51.96
7/1/2009		9/30/2009		$63.23	$49.43	$60.93
10/1/2009		12/31/2009		$70.49	$59.63	$69.41
1/4/2010		3/31/2010		$74.13	$65.40	$73.61
4/1/2010		6/30/2010		$76.93	$63.22	$64.91
7/1/2010		9/30/2010		$73.39	$64.29	$71.23
10/1/2010		12/31/2010		$79.52	$70.53	$78.72
1/3/2011		3/31/2011		$85.21	$78.33	$84.65
4/1/2011		6/30/2011		$90.00	$81.70	$88.51
7/1/2011		9/30/2011		$91.39	$67.44	$70.36
10/3/2011		12/30/2011		$79.83	$69.36	$73.09
1/3/2012		3/30/2012		$86.89	$73.90	$82.94
4/2/2012	*	4/20/2012	*	$82.73	$78.48	$81.00

As of the date of this pricing supplement, available information for the second calendar quarter of 2012 includes data for the period from April 2, 2012 through April 20, 2012. Accordingly, the Quarterly High, Quarterly Low and Quarterly Close data indicated are for this shortened period only and do not reflect complete data for the second calendar quarter of 2012.

The graph below illustrates the performance of United Technologies common stock from January 3, 2000 through April 20, 2012, based on information from Bloomberg. The dotted line represents the coupon barrier and trigger price of $56.70, which is equal to 70% of the closing price on April 20, 2012. Past performance of the underlying stock is not indicative of the future performance of the underlying stock.

What Are the Tax Consequences of the Securities?

The United States federal income tax consequences of your investment in the Securities are uncertain. Some of these tax consequences are summarized below, but we urge you to read the more detailed discussion in Supplemental U.S. Tax Considerations beginning on page PS-48 of the TPAOS product supplement and to discuss the tax consequences of your particular situation with your tax advisor.

Pursuant to the terms of the Securities, UBS and you agree, in the absence of an administrative or judicial ruling to the contrary, to characterize the Securities as a pre-paid derivative contract with respect to the underlying stock. If your Securities are so treated, you should generally recognize capital gain or loss upon the sale, automatic call, redemption or maturity of your Securities in an amount equal to the difference between the amount you receive at such time (other than with respect to a contingent coupon) and the amount you paid for your Securities. Such gain or loss should generally be long term capital gain or loss if you have held your Securities for more than one year. In addition, any contingent coupon that is paid by UBS including on the maturity date or upon automatic call should be included in your income as ordinary income in accordance with your regular method of accounting for U.S. federal income tax purposes.

Unless otherwise specified in this pricing supplement, in the opinion of our counsel, Cadwalader, Wickersham & Taft LLP, it would be reasonable to treat your Securities in the manner described above. However, because there is no authority that specifically addresses the tax treatment of the Securities, it is possible that your Securities could alternatively be treated for tax purposes in the manner described under Supplemental U.S. Tax Considerations Alternative Treatments beginning on page PS-50 of the TPAOS product supplement. The risk that the Securities may be recharacterized for United States federal income tax purposes as instruments giving rise to current ordinary income (even before receipt of any cash) and short-term capital gain or loss (even if held for more than one year), is higher than with other equity-linked securities that do not guarantee full repayment of principal.

In 2007, the Internal Revenue Service released a notice that may affect the taxation of holders of the Securities. According to the notice, the Internal Revenue Service and the Treasury Department are actively considering whether the holder of an instrument such as the Securities should be required to accrue ordinary income on a current basis. It is not possible to determine what guidance they will ultimately issue, if any. It is possible, however, that under such guidance, holders of the Securities will ultimately be required to accrue income currently in excess of any receipt of contingent coupons and this could be applied on a retroactive basis. The Internal Revenue Service and the Treasury Department are also considering other relevant issues, including whether additional gain or loss from such instruments should be treated as ordinary or capital, whether foreign holders of such instruments should be subject to withholding tax on any deemed income accruals, and whether the special constructive ownership rules of Section 1260 of the Internal Revenue Code should be applied to such instruments. Holders are urged to consult their tax advisors concerning the significance, and the potential impact, of the above considerations. Except to the extent otherwise required by law, UBS intends to treat your Securities for United States federal income tax purposes in accordance with the treatment described above and under Supplemental U.S. Tax Considerations beginning on page PS-48 of the TPAOS product supplement unless and until such time as the Treasury Department and Internal Revenue Service determine that some other treatment is more appropriate.

Moreover, in 2007, legislation was introduced in Congress that, if enacted, would have required holders of Securities purchased after the bill was enacted to accrue interest income over the term of the Securities despite the fact that there will be no interest payments over the term of the Securities. It is not possible to predict whether a similar or identical bill will be enacted in the future, or whether any such bill would affect the tax treatment of your Securities.

Beginning in 2013, U.S. holders that are individuals, estates, and certain trusts will be subject to an additional 3.8% tax on all or a portion of their net investment income, which may include any gain realized with respect to the Securities, to the extent of their net investment income that when added to their other modified adjusted gross income, exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer filing a joint return (or a surviving spouse), or $125,000 for a married individual filing a separate return. U.S. holders should consult their tax advisors with respect to their consequences with respect to the 3.8% Medicare tax.

Specified Foreign Financial Assets. Under recently enacted legislation, individuals that own specified foreign financial assets in excess of an applicable threshold may be required to file information with respect to such assets with their tax returns, especially if such assets are held outside the custody of a U.S. financial institution. You are urged to consult your tax advisor as to the application of this legislation to your ownership of the Securities.

Supplemental Plan of Distribution (Conflicts of Interest)

We have agreed to sell to UBS Financial Services Inc. and certain of its affiliates, together the Agents, and the Agents have agreed to purchase, all of the Securities at the issue price less the underwriting discount indicated on the cover of this pricing supplement, the document filed pursuant to Rule 424(b) containing the final pricing terms of the Securities.

We or one of our affiliates may enter into swap agreements or related hedge transactions with one of our other affiliates or unaffiliated counterparties in connection with the sale of the Securities and UBS or its affiliates may earn additional income as a result of payments pursuant to the swap or related hedge transactions.

Conflicts of Interest Each of UBS Securities LLC and UBS Financial Services Inc. is an affiliate of UBS and, as such, has a conflict of interest in this offering within the meaning of FINRA Rule 5121. In addition, UBS will receive the net proceeds (excluding the underwriting discount) from the initial public offering of the Securities, thus creating an additional conflict of interest within the meaning of Rule 5121. Consequently, the offering is being conducted in compliance with the provisions of Rule 5121. Neither UBS Securities LLC nor UBS Financial Services Inc. is permitted to sell Securities in this offering to an account over which it exercises discretionary authority without the prior specific written approval of the account holder.

Structured Product Categorization

To help investors identify appropriate Structured Products (Structured Products), UBS organizes its Structured Products into four categories: Protection Strategies, Optimization Strategies, Performance Strategies and Leverage Strategies. The Securities are classified by UBS as an Optimization Strategy for this purpose. The description below is intended to describe generally the four categories of Structured Products and the types of principal repayment features that may be offered on those products. This description should not be relied upon as a description of any particular Structured Product.

¨ Protection Strategies are structured to complement and provide the potential to outperform traditional fixed income instruments. These Structured Products are generally designed for investors with low to moderate risk tolerances.

¨ Optimization Strategies provide the opportunity to enhance market returns or yields and can be structured with full downside market exposure or with buffered or contingent downside market exposure. These structured products are generally designed for investors who can tolerate downside market risk.

¨ Performance Strategies provide efficient access to markets and can be structured with full downside market exposure or with buffered or contingent downside market exposure. These structured products are generally designed for investors who can tolerate downside market risk.

¨ Leverage Strategies provide leveraged exposure to the performance of an underlying asset. These Structured Products are generally designed for investors with high risk tolerances.

In order to benefit from any type of principal repayment feature, investors must hold the Securities to maturity.

Classification of Structured Products into categories is for informational purposes only and is not intended to guarantee particular results or performance.

AI assistant

UBS AG Capital/Financing Update 2012

35612_prs_2012-04-24_68357628-1be0-48c9-aa4e-89ca8862fb58.zip

AI assistant

UBS AG — Capital/Financing Update 2012

35612_prs_2012-04-24_68357628-1be0-48c9-aa4e-89ca8862fb58.zip

More from UBS AG

UBS AG Capital/Financing Update 2012